Advicenne Announces The Extension Of The Intellectual Property Of Its Drug Sibnayal
Supplementary certificates extend Sibnayal protection to 2036 in several European countries
Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, today announces the extension of the intellectual property of its drug Sibnayal in several European countries.
Advicenne has been granted Supplementary Protection Certificates (SPCs) in three of the main European pharmaceutical markets, France, Spain, and Italy. These certificates allow a five-year extension of patent protection, until 2036, in the countries where granted.
Maxime Laugier, Head of Chemistry, Manufacturing and Controls of Advicenne, highlights: “This significant strengthening of our intellectual property is excellent news for Advicenne, making it possible to extend the operating life of Sibnayal in the countries where applicable. Beyond this protection, we have developed with our industrial partners, an important know-how around the industrial use of these patents. Mastering compression for the manufacture of small tablets as well as their coating require a prominent level of technological knowledge. These elements, as well as the deployment of a new primary packaging machine, allow to market a product with high added value and erect important barriers to entry for potential competitors.”
Source: Advicenne